Biotech
NeuroThera Labs Acquires Majority Stake in CliniQuantum, Merging Quantum Computing with Clinical Trials
NeuroThera Labs Inc. has closed its acquisition of a 54.01% stake in CliniQuantum Ltd., aiming to enhance clinical trial precision through quantum simulation and Monte Carlo methods.
Quantum BioPharma Highlights Lucid-MS and unbuzzd Growth Opportunities in BioMedWire Podcast
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) was featured on The BioMedWire Podcast, where co-founder Anthony Durkacz discussed the company's lead drug candidate Lucid-MS for multiple sclerosis and its commercial alcohol metabolism product unbuzzd, emphasizing upcoming Phase 2 trials and revenue potential.
Carmed Pharmaceuticals Gains CityBiz Feature as U.S. Expansion Accelerates
Carmed Pharmaceuticals, a Turkey-based company specializing in standardized carvacrol-based formulations, is highlighted in a CityBiz Q&A with founder Mustafa Can as it expands into the U.S. market through platforms like OneLavi and Amazon.
Sunshine Biopharma Raises $6 Million in Public Offering to Fund Operations and Drug Development
Sunshine Biopharma Inc. closed a $6 million public offering to support working capital and advance its proprietary drug programs for liver cancer and SARS-related coronaviruses.
Oragenics to Present at Sidoti Micro-Cap Virtual Investor Conference Amid Progress in Neurological Therapeutics
Oragenics Inc. will present at the Sidoti Micro-Cap Virtual Investor Conference, highlighting its intranasal delivery platform and upcoming clinical trials for concussion treatment.
NanoViricides Raises $2 Million in Registered Direct Offering to Advance Antiviral Drug Pipeline
NanoViricides closes a $2 million registered direct offering with an institutional investor, providing capital to advance its broad-spectrum antiviral drug NV-387 into Phase II trials.
BioStem Technologies Posts Q1 2026 Revenue of $6.1M Amid Strategic Shift to Hospital Market
BioStem Technologies reported a net loss for Q1 2026 as it integrates BioTissue assets and pivots to hospital sales, with revenue declining from prior quarters but expecting sequential growth in H2 2026.
Dogwood Therapeutics Advances Non-Opioid Pain Pipeline with Phase 2b Data Expected This Fall
Dogwood Therapeutics reported first quarter 2026 financial results, highlighting progress in its non-opioid pain treatments Halneuron and SP16, with key clinical milestones expected in 2026.
Tonix Pharmaceuticals Reports Q1 2026 Results, Highlights TONMYA Commercial Growth and Pipeline Progress
Tonix Pharmaceuticals reported Q1 2026 financial results, showing early commercial success for its fibromyalgia drug TONMYA and advancing pipeline candidates including a Lyme disease prevention therapy.
Aclarion Reports 196% Surge in Nociscan Scans, Advances Reimbursement and Clinical Trials
Aclarion's Q1 2026 results show a 196% year-over-year increase in Nociscan scan volumes, driven by clinical adoption and payer coverage, with a strong cash position and upcoming CLARITY trial data expected in late 2026.
TransCode Therapeutics Appoints Scientific Advisory Board Chair, Partners with Michigan State University to Advance RNA-Based Cancer Therapies
TransCode Therapeutics announced the appointment of Dr. Anna Moore as Chair of its Scientific Advisory Board and a sponsored research agreement with Michigan State University to advance its RNA-based therapeutic pipeline, including lead candidate TTX-MC138.
Oncotelic Therapeutics Featured in BioMedWire Editorial on Biotech Valuation Shift
Oncotelic Therapeutics' inclusion in a BioMedWire editorial highlights how advancing drug pipelines are reshaping biotech valuations, with its AI-driven oncology pipeline and 45% stake in GMP Bio serving as examples of innovation translating into tangible enterprise value.
Biotech Valuation Shift: Drug Pipeline Progress Now Measured as Financial Assets Under GAAP
The biotech sector is experiencing a transformation where advancing drug pipelines are increasingly valued as financial assets under fair-value accounting, with companies like Oncotelic Therapeutics exemplifying how clinical progress directly impacts balance sheet valuation.
Soligenix CEO Advocates for Patient-Centric Reformulation Strategy in Rare Disease Drug Development
Soligenix CEO Christopher Schaber argues that reformulating therapies to better fit patients' daily lives can improve access, adherence, and long-term viability, highlighting a strategic shift in biopharmaceutical development.
Oncotelic Therapeutics Featured in Editorial on Biotech Valuation Trends
Oncotelic Therapeutics' diversified pipeline and strategic holdings, including a 45% stake in GMP Bio valued at over $1 billion, exemplify how scientific progress and commercialization proximity are increasingly recognized as measurable financial assets under U.S. GAAP, reflecting a broader shift in biotech valuation.
Soligenix CEO Emphasizes Capital Discipline as Key to Biotech Success in Constrained Funding Environment
Soligenix CEO Dr. Christopher J. Schaber highlights capital discipline as essential for biotech companies to navigate today's challenging funding landscape, where strategic resource allocation and milestone-focused development are critical for attracting investment and advancing programs toward commercialization.
March Biosciences Receives FDA RMAT Designation for CAR-T Therapy Targeting Aggressive T-Cell Lymphoma
The FDA granted RMAT designation to March Biosciences' MB-105 CAR-T therapy for relapsed T-cell lymphoma, potentially accelerating treatment development for patients with limited survival options.
Soligenix Reports Q3 2025 Results with Key Clinical Milestones for Rare Disease Treatments
Soligenix Inc. announced positive clinical progress for its rare disease pipeline including upcoming Phase 2a psoriasis results and maintained safety profile for HyBryte™ in CTCL treatment, supported by sufficient funding through 2026.
Datavault AI Grants Scilex Exclusive License for Biotech Exchange Platform in $2.55 Billion Deal
Datavault AI has licensed its AI-driven technology to Scilex for a biotech exchange platform that could address a $2 trillion pharmaceutical market, representing a major advancement in tokenizing and monetizing healthcare assets.
Cybin Inc. Announces Q2 2025 Financial Results and Business Update Conference Call
Cybin Inc. will host a conference call on November 13, 2025, to discuss its second-quarter financial results and provide updates on its late-stage neuropsychiatry pipeline, including breakthrough-designated psychedelic treatments for major depressive disorder and generalized anxiety disorder.
GeoVax to Report Q3 2025 Financial Results and Provide Business Update
GeoVax Labs will report its third quarter 2025 financial results and provide updates on its clinical-stage vaccine and immunotherapy programs, including COVID-19 vaccines for immunocompromised patients and oncology treatments.
Soligenix Strengthens CTCL Advisory Board to Advance HyBryte Therapy Development
Soligenix has updated its U.S. Medical Advisory Board for cutaneous T-cell lymphoma to support the clinical advancement of HyBryte and related therapies, reflecting the company's strategic focus on navigating complex regulatory and commercialization challenges in the rare disease space.
ABVC BioPharma Reports 230% Licensing Revenue Growth and Major Asset Expansion in Q3 2025
ABVC BioPharma achieved significant financial growth with 230% year-over-year licensing revenue increase and 181% asset expansion, driven by strategic investments in Taiwan manufacturing facilities that strengthen the company's global dual-core operational structure.
Cancer Treatment Support Needs Drive Biotech Innovation
The emotional and physical challenges faced by cancer patients during treatment are motivating biotech companies like Soligenix to develop new therapeutic approaches while highlighting the importance of patient-focused support strategies.
Alpha Cognition Secures $35 Million in Oversubscribed Public Offering to Accelerate Neurodegenerative Disease Treatment Commercialization
Alpha Cognition's successful $35 million public offering will accelerate commercialization of its Alzheimer's treatment ZUNVEYL and advance development of other neurodegenerative disease therapies, addressing critical unmet medical needs.
Oncotelic Therapeutics CEO Outlines Key Clinical Milestones in BioMedWire Podcast Interview
Oncotelic Therapeutics CEO Dr. Vuong Trieu discussed the company's upcoming clinical and regulatory milestones in oncology and rare disease treatments during a recent podcast appearance, highlighting potential catalysts for investor attention.
Oncotelic Therapeutics Advances Late-Stage Oncology Pipeline Under Proven Leadership
Oncotelic Therapeutics is progressing multiple late-stage clinical programs in high-unmet-need oncology indications under CEO Dr. Vuong Trieu, whose track record with blockbuster cancer drugs positions the company for potential therapeutic breakthroughs.
Oncotelic Therapeutics CEO's Patent Portfolio and Track Record Position Company for Oncology Market Growth
Oncotelic Therapeutics' CEO Dr. Vuong Trieu, developer of Abraxane, brings extensive patent expertise and successful drug development experience that strengthens the company's position in advancing innovative cancer therapies with significant market potential.
Quantum BioPharma Receives Health Canada Product License for Qlarity Natural Health Product
Quantum BioPharma Ltd. has secured Health Canada approval for its Qlarity natural health product, expanding its market reach and revenue potential through regulatory clearance for cognitive and energy support supplements.
Nutriband Secures $5.3 Million Through Warrant Exercises, Bolstering AVERSA™ Fentanyl Development
Nutriband Inc. raised $5.3 million through voluntary warrant exercises at $6.43 per share, demonstrating strong investor confidence in its abuse-deterrent transdermal patch technology AVERSA™ Fentanyl ahead of its FDA submission.